ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.72
0.20%
US Tech 100
20,302.80
0.35%
S&P 500
6,002.53
0.56%
US Dollar vs CAD
1.39787
-0.01%
Bitcoin
96,178.88
-1.90%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Apollomics Inc (APLMW)

  7. Apollomics Inc (APLMW) News

APLMW

Apollomics (APLMW)

Apollomics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:APLMW
DateTimeSourceHeadlineSymbolCompany
11/14/20244:25PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APLMWApollomics Inc
11/01/20243:10PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APLMWApollomics Inc
08/13/20249:50AMAllPennyStocks.comBiotech Sees Massive Buying Pressure Following Phase 2 Preliminary DataNASDAQ:APLMWApollomics Inc
06/04/20247:00AMGlobeNewswire Inc.Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:APLMWApollomics Inc
05/30/20243:15PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLMWApollomics Inc
05/29/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APLMWApollomics Inc
05/29/20244:12PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:APLMWApollomics Inc
05/29/20247:00AMGlobeNewswire Inc.Apollomics Announces Presentation at the 2024 BIO International ConventionNASDAQ:APLMWApollomics Inc
05/24/20244:03PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APLMWApollomics Inc
05/24/20243:58PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLMWApollomics Inc
05/20/20243:32PMEdgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:APLMWApollomics Inc
05/20/20243:15PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLMWApollomics Inc
05/20/20243:15PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLMWApollomics Inc
05/08/20243:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APLMWApollomics Inc
05/08/20243:05PMGlobeNewswire Inc.Apollomics Announces Private Placement Financing and Addition to Board of DirectorsNASDAQ:APLMWApollomics Inc
04/25/20247:30AMGlobeNewswire Inc.Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneNASDAQ:APLMWApollomics Inc
04/10/20246:00AMGlobeNewswire Inc.Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
04/02/20247:00AMGlobeNewswire Inc.Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
03/28/20246:00AMGlobeNewswire Inc.Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsNASDAQ:APLMWApollomics Inc
03/26/20247:00AMGlobeNewswire Inc.Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024NASDAQ:APLMWApollomics Inc
03/04/20246:00AMGlobeNewswire Inc.Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerNASDAQ:APLMWApollomics Inc
02/07/20246:00AMGlobeNewswire Inc.Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:APLMWApollomics Inc
01/19/20243:15PMGlobeNewswire Inc.Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:APLMWApollomics Inc
01/17/20243:30PMGlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceNASDAQ:APLMWApollomics Inc
01/03/20246:00AMGlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:APLMWApollomics Inc
01/02/20243:30PMGlobeNewswire Inc.Apollomics to Present at the 2024 Biotech ShowcaseNASDAQ:APLMWApollomics Inc
12/04/20236:00AMGlobeNewswire Inc.Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNASDAQ:APLMWApollomics Inc
11/29/20236:30AMGlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:APLMWApollomics Inc
11/28/20236:00AMGlobeNewswire Inc.Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)NASDAQ:APLMWApollomics Inc
11/16/20237:30AMGlobeNewswire Inc.Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerNASDAQ:APLMWApollomics Inc
 Showing the most relevant articles for your search:NASDAQ:APLMW

Your Recent History

BIT
S30581
Societe Generale Effekten
BIT
ECRD
ETFS EUR Daily Hedged Wt...
BIT
P1P6X3
BNP Paribas Issuance
BIT
P1R5Z8
BNP Paribas Issuance
TG
TGBT
VanEck ETFs NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved